News
All news from Vismederi Holding
Bundibugyo ebolavirus: supporting vaccine development for an emerging public health threat
First identified in Uganda in 2007, Bundibugyo ebolavirus is one of the species of the Ebola virus. Although it has historically shown a lower case fatality rate than some other Ebola virus species, typically between 25% and 40%, it remains a serious public health...
VisMederi Expands Its Service Portfolio with End-to-End Sample Kit Management
From kit design and manufacturing to biological sample management and laboratory testing, VisMederi offers a fully integrated solution for clinical trials and research programs worldwide. VisMederi, a company specialized in vaccine evaluation through advanced...
VisMederi and CEVAC Sign Memorandum of Understanding to Strengthen Vaccine Clinical Trial Capabilities in Europe
VisMederi and CEVAC, a Belgian vaccine research center comprising a Clinical Trial Unit and an Immunomonitoring Laboratory, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in vaccine clinical trials, a core area of expertise for...
VisMederi and KingMylab Sign Strategic Partnership to Strengthen Global Clinical Trial Testing Services for Vaccines and Biologics
VisMederi and KingMylab have announced the signing of a strategic collaboration agreement aimed at strengthening testing and analytical services for vaccine and biologics clinical trials. The partnership combines KingMylab’s expertise in central laboratory...
VisMederi signs vaccine research partnership with GCCL at World Vaccine Congress 2026
VisMederi announces the signing of a Memorandum of Understanding with Global Clinical Central Lab, an international company specializing in clinical trial services, at the World Vaccine Congress 2026, one of the leading global events dedicated to the vaccine...
Universal influenza vaccine candidate, collaboration with Sumitomo Pharma Co., Ltd. and Japan’s National Institutes of Biomedical Innovation Health and Nutrition (NIBN)
VisMederi highlighted its collaboration with Sumitomo Pharma Co., Ltd. and Japan’s National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in the European Phase 1 clinical programme evaluating a universal influenza vaccine candidate formulated...
